CoreComm Internet

Features

Make this your home page

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22. 8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 pounds (15 kilograms). That's according to the study funded by Lilly, which was published Sunday in the New of of...

Read More
 

----------
Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

CoreComm is not responsible for content on external sites. Please review the privacy and security policies of each vendor before making online purchases or providing personal information. Forecast Information Provided by AccuWeather.